GE Healthcare Announces European Union Approval Of VIZAMYL (Flutemetamol (18F) Solution For Injection) For PET Imaging Of Beta Amyloid Plaque In Suspected Alzheimer’s Disease
9/2/2014 12:06:11 PM
CHALFONT ST. GILES, England--(BUSINESS WIRE)--GE Healthcare announced today that VIZAMYL™ (flutemetamol (18F) solution for injection) has received marketing authorisation from the European Commission as a radiopharmaceutical medicinal product indicated for Positron Emission Tomography (PET) imaging of beta amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. VIZAMYL™ is the only PET imaging tracer for detection of amyloid approved in Europe for visual interpretation of colour images and will be commercially available in selected European countries from early 2015. VIZAMYL™ is for diagnostic use only and should be used in conjunction with a clinical evaluation.
Help employers find you! Check out all the jobs and post your resume.
comments powered by